Marshall Wace, LLP Aravive, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.19 - $4.07 $62,331 - $115,840	-28,462 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.67 - $5.8 $598,055 - $945,156	-162,958 Reduced 85.13%	28,462 $106,000
Q2 2021 Aug 13, 2021	BUY	$4.65 - $6.42 $598,036 - $825,676	128,610 Added 204.76%	191,420 $1.14 Million
Q1 2021 May 17, 2021	BUY	$5.11 - $9.24 $219,965 - $397,745	43,046 Added 217.8%	62,810 $414,000
Q4 2020 Feb 16, 2021	SELL	$4.36 - $6.51 $94,075 - $140,466	-21,577 Reduced 52.19%	19,764 $111,000
Q3 2020 Nov 16, 2020	BUY	$4.7 - $12.06 $194,302 - $498,572	41,341 New	41,341 $194,000
Q1 2019 May 14, 2019	SELL	$3.35 - $8.27 $20 - $49	-6 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.23 - $8.7 $19 - $52	6 New	6 $0

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.